- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 13, 2019
Distillery Therapeutics
Inhibiting B3GALT5 or its biosynthetic products for breast and pancreatic cancers
BioCentury | Jul 21, 2017
Company News
OBI gains ThioBridge linker tech from Abzena for OBI-999 and other ADCs
BioCentury | Apr 28, 2016
Distillery Therapeutics
Therapeutics: Stage-specific embryonic antigen-4 (SSEA-4); integrin β4
BioCentury | Dec 18, 2014
Distillery Therapeutics
Therapeutics: Globohexaosylceramide (globo-H); stage-specific embryonic antigen-3 (SSEA-3); SSEA-4
Items per page:
1 - 5 of 5